US 12,065,408 B2
Benzaldehyde compounds with direct polymer destabilizing effects to treat sickle cell disease
Martin Safo, Richmond, VA (US); Yan Zhang, Glen Allen, VA (US); Andrew Fleischman, Henrico, VA (US); David Light, Henrico, VA (US); Moustafa El-Araby, Jeddah (SA); Abdelsattar Omar, Jeddah (SA); and Osheiza Abdulmalik, Philadelphia, PA (US)
Assigned to VIRGINIA COMMONWEALTH UNIVERISTY, Richmond, VA (US); KING ABDULAZIZ UNIVERSITY, Jeddah (SA); CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP), Philadelphia, PA (US); and ILLEXCOR HOLDINGS, LLC, Henrico, VA (US)
Filed by VIRGINIA COMMONWEALTH UNIVERSITY, Richmond, VA (US); IIIExcor Holdings, LLC, Henrico, VA (US); KING ABDULAZIZ UNIVERSITY, Jeddah (SA); and CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP), Philadelphia, PA (US)
Filed on Nov. 3, 2023, as Appl. No. 18/386,724.
Claims priority of provisional application 63/423,167, filed on Nov. 7, 2022.
Claims priority of provisional application 63/442,824, filed on Feb. 2, 2023.
Prior Publication US 2024/0174612 A1, May 30, 2024
Int. Cl. C07D 213/30 (2006.01); A61P 7/06 (2006.01); C07D 239/26 (2006.01)
CPC C07D 213/30 (2013.01) [A61P 7/06 (2018.01); C07D 239/26 (2013.01)] 11 Claims
 
1. A compound having a formula

OG Complex Work Unit Chemistry
wherein
W, X, Y and Z are the same or different and are independently C or N, with the proviso that at least one of W, X, Y and Z is N; and
R1, R2, R3, and Ra are the same or different and independently F, Cl or H, and pharmaceutically acceptable salts or oral prodrugs thereof.